In the literature, there are very few data about the expression of PD-L1 on CTCs in patients diagnosed with NSCLC and melanoma but, to the best of our knowledge, our study is the first to analyze PD-L1 expression on CTCs isolated from patients with chemorefractory mCRC in the era of regorafenib. The gene discussed is CD274; the disease is melanoma.